JP2021514967A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021514967A5 JP2021514967A5 JP2020544744A JP2020544744A JP2021514967A5 JP 2021514967 A5 JP2021514967 A5 JP 2021514967A5 JP 2020544744 A JP2020544744 A JP 2020544744A JP 2020544744 A JP2020544744 A JP 2020544744A JP 2021514967 A5 JP2021514967 A5 JP 2021514967A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- crystal type
- crystal
- spectrum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 claims 128
- 150000001875 compounds Chemical class 0.000 claims 108
- 238000001228 spectrum Methods 0.000 claims 57
- 238000000634 powder X-ray diffraction Methods 0.000 claims 48
- 238000010521 absorption reaction Methods 0.000 claims 18
- 238000010183 spectrum analysis Methods 0.000 claims 12
- 229940126214 compound 3 Drugs 0.000 claims 9
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 8
- 238000004458 analytical method Methods 0.000 claims 7
- 238000001757 thermogravimetry curve Methods 0.000 claims 5
- 230000003247 decreasing effect Effects 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 0 CNc1c(C=C(*)F)c(-c(nc2N[C@@](C3CCC4CC3)[C@]4C(O)=O)nc(C3CC3)c2F)n[n]1 Chemical compound CNc1c(C=C(*)F)c(-c(nc2N[C@@](C3CCC4CC3)[C@]4C(O)=O)nc(C3CC3)c2F)n[n]1 0.000 description 5
- JCHDJLSIYWBAHI-ZWHBIUKWSA-M [O-]C([C@@H](C1CCC2CC1)[C@H]2Nc1nc(-c2n[nH]c(nc3)c2cc3F)nc(C2CC2)c1F)=O Chemical compound [O-]C([C@@H](C1CCC2CC1)[C@H]2Nc1nc(-c2n[nH]c(nc3)c2cc3F)nc(C2CC2)c1F)=O JCHDJLSIYWBAHI-ZWHBIUKWSA-M 0.000 description 3
- JCHDJLSIYWBAHI-ZWHBIUKWSA-N OC([C@@H](C1CCC2CC1)[C@H]2Nc1nc(-c(c2c3)n[nH]c2ncc3F)nc(C2CC2)c1F)=O Chemical compound OC([C@@H](C1CCC2CC1)[C@H]2Nc1nc(-c(c2c3)n[nH]c2ncc3F)nc(C2CC2)c1F)=O JCHDJLSIYWBAHI-ZWHBIUKWSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N Cc(cc1)ccc1S(O)(=O)=O Chemical compound Cc(cc1)ccc1S(O)(=O)=O JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- DMOZUCZSFXHEMB-ZWHBIUKWSA-N OC([C@@H](C1CCC2CC1)[C@H]2Nc1nc(-c2n[nH]c(NC3)c2C=C3F)nc(C2CC2)c1F)=O Chemical compound OC([C@@H](C1CCC2CC1)[C@H]2Nc1nc(-c2n[nH]c(NC3)c2C=C3F)nc(C2CC2)c1F)=O DMOZUCZSFXHEMB-ZWHBIUKWSA-N 0.000 description 1
- FYNIKNPUVOGKCL-QZTMADQPSA-N OC([C@@H](C1CCC2CC1)[C@H]2Nc1nc(-c2n[nH]c(NC3)c2CC3F)nc(C2CC2)c1F)=O Chemical compound OC([C@@H](C1CCC2CC1)[C@H]2Nc1nc(-c2n[nH]c(NC3)c2CC3F)nc(C2CC2)c1F)=O FYNIKNPUVOGKCL-QZTMADQPSA-N 0.000 description 1
- VBYBPOYZLJMQSA-SUMWQHHRSA-M [O-]C([C@@H]1[C@@H](Nc2nc(-c(c3c4)n[nH]c3ncc4F)nc(C3CC3)c2F)[I]2CCC1CC2)=O Chemical compound [O-]C([C@@H]1[C@@H](Nc2nc(-c(c3c4)n[nH]c3ncc4F)nc(C3CC3)c2F)[I]2CCC1CC2)=O VBYBPOYZLJMQSA-SUMWQHHRSA-M 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810180641.8 | 2018-03-05 | ||
| CN201810180641 | 2018-03-05 | ||
| PCT/CN2019/076916 WO2019170067A1 (zh) | 2018-03-05 | 2019-03-05 | 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514967A JP2021514967A (ja) | 2021-06-17 |
| JP2021514967A5 true JP2021514967A5 (enExample) | 2021-07-29 |
| JP7031002B2 JP7031002B2 (ja) | 2022-03-07 |
Family
ID=67846865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544744A Active JP7031002B2 (ja) | 2018-03-05 | 2019-03-05 | ピリジノイミダゾール系化合物の結晶型、塩型及びその製造方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11535613B2 (enExample) |
| EP (1) | EP3763713A4 (enExample) |
| JP (1) | JP7031002B2 (enExample) |
| KR (1) | KR102484804B1 (enExample) |
| CN (1) | CN111819177B (enExample) |
| AU (1) | AU2019230497B2 (enExample) |
| CA (1) | CA3092315C (enExample) |
| NZ (1) | NZ767352A (enExample) |
| RU (1) | RU2769050C1 (enExample) |
| TW (1) | TWI794433B (enExample) |
| WO (1) | WO2019170067A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX394277B (es) * | 2016-09-05 | 2025-03-24 | Guangdong Raynovent Biotech Co Ltd | Derivados de pirimidina contra virus de la influenza |
| CN114127068B (zh) * | 2019-07-22 | 2024-05-28 | 广东众生睿创生物科技有限公司 | 嘧啶衍生物的优势盐型及其晶型 |
| CN114502150B (zh) * | 2019-09-10 | 2023-03-24 | 广东众生睿创生物科技有限公司 | 一种用于治疗病毒性感冒的药物组合物及其制剂 |
| CN113116899B (zh) * | 2020-03-06 | 2022-12-20 | 广东众生睿创生物科技有限公司 | 一种用于治疗流感的药物组合物及含有该药物组合物的制剂 |
| WO2022089261A1 (zh) * | 2020-10-29 | 2022-05-05 | 广东众生睿创生物科技有限公司 | 一种嘧啶衍生物的晶型及其制备方法 |
| EP4286386A4 (en) * | 2021-02-03 | 2025-03-12 | Ocumension Therapeutics (Suzhou) Co., Ltd. | Salt form and crystal form of a pyrazole-substituted imidazo[1,2-a]quinoxaline derivative |
| JP2024509939A (ja) * | 2021-03-11 | 2024-03-05 | シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド | ピリジン窒素酸化物の結晶形態およびその使用 |
| WO2025237212A1 (zh) * | 2024-05-11 | 2025-11-20 | 广东众生睿创生物科技有限公司 | 一种嘧啶衍生物葡甲胺盐及其晶型 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20207129B (en) * | 2009-06-17 | 2020-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
| RU2013132681A (ru) * | 2010-12-16 | 2015-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы репликации вирусов гриппа |
| MX341342B (es) * | 2011-01-14 | 2016-08-17 | Vertex Pharma | Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea. |
| EA201790266A1 (ru) | 2014-08-08 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Индолы для применения при инфекции, вызванной вирусом гриппа |
| EP3362451B1 (en) | 2015-12-09 | 2023-04-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| WO2017133670A1 (en) | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
| WO2017133667A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof |
| JP7129339B2 (ja) * | 2016-03-07 | 2022-09-01 | ハイテック パワー，インコーポレーテッド | 内燃エンジン用第２燃料を発生させかつ分配する方法 |
| MX394277B (es) * | 2016-09-05 | 2025-03-24 | Guangdong Raynovent Biotech Co Ltd | Derivados de pirimidina contra virus de la influenza |
-
2019
- 2019-03-05 NZ NZ767352A patent/NZ767352A/en unknown
- 2019-03-05 JP JP2020544744A patent/JP7031002B2/ja active Active
- 2019-03-05 CN CN201980013553.1A patent/CN111819177B/zh active Active
- 2019-03-05 WO PCT/CN2019/076916 patent/WO2019170067A1/zh not_active Ceased
- 2019-03-05 US US16/975,600 patent/US11535613B2/en active Active
- 2019-03-05 TW TW108107240A patent/TWI794433B/zh active
- 2019-03-05 RU RU2020131044A patent/RU2769050C1/ru active
- 2019-03-05 KR KR1020207027160A patent/KR102484804B1/ko active Active
- 2019-03-05 AU AU2019230497A patent/AU2019230497B2/en active Active
- 2019-03-05 EP EP19763994.1A patent/EP3763713A4/en active Pending
- 2019-03-05 CA CA3092315A patent/CA3092315C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530565A5 (enExample) | ||
| JP4511191B2 (ja) | Ｏ−シクロプロピル−カルボキサニリド及びそれらの殺真菌剤としての使用 | |
| FI4058151T3 (fi) | Terfenyyliyhdisteen uusi suola | |
| JP2007532560A5 (enExample) | ||
| JP2010516681A5 (enExample) | ||
| JP2008520742A5 (enExample) | ||
| JP2018024682A5 (enExample) | ||
| RU2009131727A (ru) | Макроциклические полиморфы, композиции, содержащие такие полиморфы, и способы их применения и получения | |
| JP2007519721A5 (enExample) | ||
| JP2012530765A5 (enExample) | ||
| JP2019504103A5 (enExample) | ||
| JP2012533550A5 (enExample) | ||
| JP2009533323A5 (enExample) | ||
| CA2654315A1 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and their use | |
| JP2016537326A5 (enExample) | ||
| JP2011500575A5 (enExample) | ||
| CN111386268A (zh) | 一种urat1抑制剂的晶型及其制备方法 | |
| RU2015113277A (ru) | Кристаллическтие соединения | |
| JP2016510767A5 (enExample) | ||
| JP2015531354A5 (enExample) | ||
| RU2015114085A (ru) | Кристаллические формы производных дигидропиримидина | |
| JP2020517676A5 (enExample) | ||
| CN111417633A (zh) | 一种β-内酰胺酶抑制剂的晶型及其制备方法 | |
| JP2018509421A5 (enExample) | ||
| JP2010540440A5 (enExample) |